{"nctId":"NCT02284893","briefTitle":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","startDateStruct":{"date":"2014-09-09","type":"ACTUAL"},"conditions":["Type 2 Diabetes"],"count":461,"armGroups":[{"label":"A1:Saxagliptin / Placebo + Dapagliflozin / Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Dapagliflozin","Drug: Placebo matching with Saxagliptin","Drug: Placebo matching with Dapagliflozin"]},{"label":"A2: Sitagliptin / placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Placebo matching with Sitagliptin"]}],"interventions":[{"name":"Saxagliptin","otherNames":[]},{"name":"Dapagliflozin","otherNames":[]},{"name":"Sitagliptin","otherNames":[]},{"name":"Placebo matching with Saxagliptin","otherNames":[]},{"name":"Placebo matching with Dapagliflozin","otherNames":[]},{"name":"Placebo matching with Sitagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control, defined as a central laboratory glycosylated hemoglobin (HbA1c) ≥8.0% and ≤ 10.5 % obtained at the screening visit\n* Subjects should have been taking the same daily dose of metformin ≥ 1500 mg for at least 8 weeks prior to the enrollment visit and with no intake of other antihyperglycemic therapy for more than 14 days (consecutive or not) during 12 weeks prior to screening\n* BMI \\> 20.0 kg/m2 at the enrollment visit\n* Males and Females, age ≥18 years old at time of screening visit\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug\n* Women must not be breastfeeding\n\nExclusion Criteria:\n\n* Clinically diagnosed with Type I diabetes, known diagnosis of Maturity Onset Diabetes of Young (MODY), secondary diabetes mellitus or diabetes insipidus\n* History of diabetic ketoacidosis\n* Any of the following cardiovascular (CV)/Vascular Diseases within 3 months of the enrollment visit\n\n  * Myocardial infarction\n  * Cardiac surgery or revascularization (coronary artery bypass surgery Coronary Artery Bypass Graft \\[(CABG)\\]/percutaneous transluminal coronary angioplasty percutaneous transluminal coronary angioplasty \\[(PTCA)\\])\n  * Unstable angina\n  * Unstable congestive heart failure (CHF)\n  * Transient ischemic attack (TIA) or significant cerebrovascular disease\n  * Unstable or previously undiagnosed arrhythmia\n  * Congestive heart failure, defined as New York Heart Association (NYHA) Class III and IV, unstable or acute congestive heart failure and/or known left ventricular ejection fraction of ≤ 40%\n* Renal Disease\n* Hepatic Diseases\n* Hematological and Oncological Disease/Conditions\n* Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women\n* Abnormal Free T4","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in HbA1c","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.41","spread":"0.0696"},{"groupId":"OG001","value":"-1.07","spread":"0.0719"}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":"3.150"},{"groupId":"OG001","value":"25.1","spread":"2.871"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Total Body Weight","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":"0.2010"},{"groupId":"OG001","value":"-0.51","spread":"0.2078"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Fasting Plasma Glucose (FPG)","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.9","spread":"2.538"},{"groupId":"OG001","value":"-11.0","spread":"2.668"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":232},"commonTop":["NASOPHARYNGITIS","HEADACHE","INFLUENZA","URINARY TRACT INFECTION","UPPER RESPIRATORY TRACT INFECTION"]}}}